

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27](#).

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration in the USA](#), the [European Medicines Agency](#) and the [Therapeutic Goods Administration](#).

A:

ANSWERS TO SELF-TEST QUESTIONS

- 1 True 2 False
- 3 False 4 True

Corrections

Management of insomnia in primary care [Correction]

Aust Prescr 2021;44:177

First published 10 August 2021

<https://doi.org/10.18773/austprescr.2021.043>

The article on management of insomnia in primary care (Aust Prescr 2021;44:124-8) has been corrected. [View corrected article.](#)

In the drug management paragraph on melatonin, the treatment duration should have been over a ‘three-week period’ rather than a 13-week period: “Melatonin (2 mg extended-release formulation) is effective in treating insomnia in adults over the age of 55 over a three-week period.”

The ocular adverse effects of oral drugs [Correction]

Aust Prescr 2021;44:177

First published 13 August 2021

<https://doi.org/10.18773/austprescr.2021.045>

The article on adverse effects of oral drugs on the eye (Aust Prescr 2021;44:129-36) has been corrected. [View corrected article.](#)

Table 1, showing common or serious ocular adverse effects of selected oral drugs, incorrectly listed dutasteride and finasteride as alpha₁ adrenergic receptor antagonists (row 1). These drugs have now been removed from the table.

EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

Postal The Editor
Australian Prescriber
 GPO Box 266
 Canberra, ACT 2600

Telephone +61 2 8217 8700

Email info@australianprescriber.com

Website nps.org.au/australian-prescriber

Twitter @AustPrescriber

SUBSCRIPTIONS

Australian Prescriber is published every two months online. All content is accessible free of charge in full text at nps.org.au/australian-prescriber. New drugs are published between issues as they become available.

An email alert can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at nps.org.au/australian-prescriber

For free copies of the Anaphylaxis wallchart and Switching-antidepressants poster, order online at www.nps.org.au/order#for-health-professionals

© 2021 NPS MedicineWise
 ABN 61 082 034 393

NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.